RE:RE:New Press Release - Oncolytics Biotech® Announces Productive FDA Type C Meeting on its Metastatic Breast Cancer ProgramAs Matt Coffey previously stated .. " The Company's proposed study will enroll patients who have failed hormonal therapy and have received no more than one line of antibody-drug conjugate (ADC) therapy " .. which is an unmet need since ADCs result in T cell exhaustion and have significant "black box" adverse side effects (including grade 5 patient deaths).
ONCY's AWARE-1 Phase 2 study has identified biomarkers and surrogate endpoints including Cel-TiLs that demonstrated pelareorep's effectiveness as an 'enabling' immunotherapeutic agent for other I/O agents.
"Pelareorep profoundly reverses immunosuppressive tumor microenvironments and promotes immune effector cell infiltration into solid tumors, positioning it as an enabling technology for a variety of immunotherapeutic agents"
https://www.prnewswire.com/news-releases/oncolytics-biotech-and-solti-achieve-primary-endpoint-in-aware-1-study-301266442.html